(Q43617842)

25 November 2017

0 references

Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines (English)

1 reference

25 November 2017

Simoes EA

1

1 reference

25 November 2017

Tan DH

2

1 reference

25 November 2017

Ohlsson A

3

1 reference

25 November 2017

Sales V

4

1 reference

25 November 2017

Wang EE

5

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

20

1 reference

25 November 2017

issue

5-6

1 reference

25 November 2017

page(s)

954-960

1 reference

Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Economic impact of viral respiratory disease in children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Immunity to and frequency of reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Reducing the morbidity of lower respiratory tract infections caused by respiratory syncytial virus: still no answer

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Prospects for a respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Respiratory syncytial virus and influenza A infections in the hospitalized elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Methodology and Reports of Systematic Reviews and Meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

Safety and immunogenicity of the PFP vaccine against respiratory syncytial virus (RSV): the western blot assay aids in distinguishing immune responses of the PFP vaccine from RSV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2801%2900388-7

7 January 2021

10.1016/S0264-410X(01)00388-7

Identifiers

DOI

1 reference

25 November 2017

1 reference